These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8593449)

  • 1. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy.
    Shibata N; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between apparent total body clearance of cyclosporin A and its erythrocyte-to-plasma distribution ratio in renal transplant patients.
    Shibata N; Minouchi T; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
    Biol Pharm Bull; 1995 Jan; 18(1):115-21. PubMed ID: 7735224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for predicting the cyclosporin A erythrocyte-to-plasma distribution ratio in blood, and its clinical assessment.
    Shibata N; Yamaji A; Park K; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y; Hodohara K; Hosoda S
    Biol Pharm Bull; 1994 May; 17(5):709-14. PubMed ID: 7920439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
    Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K
    Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal cyclosporine therapy--an Indian experience.
    Raj DS; Somiah S; Mani K
    J Assoc Physicians India; 1996 Jan; 44(1):34-6. PubMed ID: 8773092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.
    Kokuhu T; Fukushima K; Ushigome H; Yoshimura N; Sugioka N
    Int J Med Sci; 2013; 10(12):1665-73. PubMed ID: 24151438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
    Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience.
    Zakliczyński M; Szewczyk M; Zakliczyńska H; Zembala M
    Ann Transplant; 2005; 10(2):38-45. PubMed ID: 16218032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
    Sud K; Muthukumar T; Singh B; Garg SK; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):647-9. PubMed ID: 11256238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.
    Okada A; Ushigome H; Kanamori M; Morikochi A; Kasai H; Kosaka T; Kokuhu T; Nishimura A; Shibata N; Fukushima K; Yoshimura N; Sugioka N
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1111-1119. PubMed ID: 28620753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation.
    Pan SH; Lopez RR; Sher LS; Hoffman AL; Podesta LG; Makowka L; Rosenthal P
    Pharmacotherapy; 1996; 16(1):59-65. PubMed ID: 8700793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
    Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M
    Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994
    [No Abstract]   [Full Text] [Related]  

  • 17. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
    Foradori A; Pinto VM; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy.
    Ishizawa T; Sugawara Y; Ikeda M; Hasegawa K; Makuuchi M
    Transplant Proc; 2005 Dec; 37(10):4370-2. PubMed ID: 16387123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte-to-plasma distribution ratio of cyclosporine: a useful indicator to predict cyclosporine pharmacokinetics and physiological changes during cyclosporine monitoring.
    Shibata N; Hoshino N; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
    Transplant Proc; 1996 Jun; 28(3):1313-5. PubMed ID: 8658674
    [No Abstract]   [Full Text] [Related]  

  • 20. A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients.
    Shibata N; Hayakawa T; Hoshino N; Minouchi T; Yamaji A
    Biol Pharm Bull; 1997 Aug; 20(8):897-903. PubMed ID: 9300138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.